Silence Therapeutics plc financials

SLN CIK 0001479615

Source: EDGAR filings · Built 2026-06-19T03:09:07Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -62.33M -67.85M -49.52M -57.22M
EBITDA -90.77M -62.98M -64.01M -60.66M
Working Capital 105.05M 170.54M 80.81M
Net Debt -11.12M -121.21M -68.44M
Gross Margin 61.54% 72.70% 59.34% 37.83%
Operating Margin -16292.84% -146.38% -203.47% -281.87%
Net Margin -15851.88% -104.74% -171.37% -232.44%
Return on Equity (ROE) -142.23% -33.81% -246.57% -184.91%
Return on Assets (ROA) -67.42% -22.36% -45.40%
Current Ratio 8.72× 11.14× 4.62×
Debt-to-Equity 0.00× 0.00× 0.02×
Effective Tax Rate -0.01% -1.90% -1.79% -1.39%
Cash Conversion Ratio 0.70× 1.49× 0.91× 1.13×
Accruals Ratio -0.20× 0.11× -0.04×
SBC % of Revenue 1444.36% 37.70% 51.43% 58.58%
CapEx Coverage -1132.20× -320.57× -883.25× -329.73×
Free Cash Flow Per Share $-0.44 $-0.49 $-0.45 $-0.59

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 559.00K 43.26M 31.64M 21.66M
Cost of Goods and Services Sold 215.00K 11.81M 12.87M 13.46M
Gross Profit 344.00K 31.45M 18.78M 8.19M
Research and Development Expense 67.75M 67.88M 56.94M 43.55M
Operating Income (Loss) -91.08M -63.32M -64.38M -61.04M
Income Tax Expense (Benefit) 11.00K 845.00K 956.00K 688.00K
Net Income (Loss) Attributable to Parent -88.61M -45.31M -54.23M -50.33M
Earnings Per Share, Basic $-0.63 $-0.33 $-0.49 $-0.52
Weighted Average Number of Shares Outstanding, Basic 141.69M 138.75M 111.28M 96.58M
Earnings Per Share, Diluted $-0.63 $-0.33 $-0.49 $-0.52
Weighted Average Number of Shares Outstanding, Diluted 141.69M 138.75M 111.28M 96.58M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 11.28M 121.33M 68.79M
Assets, Current 118.66M 187.37M 103.15M
Assets 131.44M 202.63M 119.45M
Liabilities, Current 13.61M 16.82M 22.34M
Liabilities 69.14M 68.61M 97.45M
Stockholders' Equity Attributable to Parent 62.30M 134.02M 21.99M 27.22M 12.37M
Common Stock, Shares, Outstanding 141.70M 141.67M 118.85M 107.81M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -62.27M -67.64M -49.46M -57.04M
Payments to Acquire Property, Plant, and Equipment 55.00K 211.00K 56.00K 173.00K
Net Cash Provided by (Used in) Investing Activities -47.99M -21.97M 19.29M -20.50M
Net Cash Provided by (Used in) Financing Activities 15.00K 142.09M 31.94M 52.58M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (SLN CIK 0001479615), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CNDIF

CANADIAN IMPERIAL BANK OF COMMERCE /CAN/

LTCH

Latch, Inc.

TFC-PI

TRUIST FINANCIAL CORP